Ligand Pharmaceuticals Inc.

LGND · Pharmaceutical Preparations · $5.7B

Cooling off

biotech-health

LGND

$283.49

▼ −0.43%

09/18 O 285.63 H 285.64 L 280.49 C 283.49 ▼ −0.43%
Vol 372.8K RS 81

RS rating81

Now vs pivot (%)−13.21%

Tightening (ATR ratio)1.29×

Volume dry-up1.56×

Up/down volume, net-0.29

From 52-week high13%

forming

Previous breakout trailed out ▲ +15.85% in Jun

Moving averages

9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 10.4 weeks and fell 17% from its ceiling at its deepest. The pivot is $326.63, and the stock closed 13.2% below it. Its relative strength rating is 81.

Peers

Same industry

ANRO99 ERAS99 ABCL98 CLYM98 ETON98 IMMX98 MBX98 NVCT98

Same theme

ANRO99 ERAS99 MRNA99 ABCL98 CLYM98 ETON98 IMMX98 MBX98

Catalyst roadmap

EarningstentativeLLY · competitorin 41d
LLY reports
Oct 29, 2026
Add to calendar
Earningstentativein 48d
Quarterly earnings
Nov 5, 2026
Add to calendar

Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news

No headlines for this company in the last couple of weeks.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray